Excyte Biopharma Ltd

This early-stage study tests a new drug, YK012, in 72 adults with primary membranous nephropathy, a kidney disease that causes protein leakage. The main goals are to check the drug's safety and how the body processes it. Researchers will also look for early signs that the drug mi…

This early-stage trial tests a new medicine, YKST02, in about 70 people whose multiple myeloma has returned or not responded to at least two prior treatments. The drug is designed to help the body's immune system fight the cancer. The main goals are to check safety and find the r…

This early-stage study tests a new drug called YK012 in 48 adults whose B-cell non-Hodgkin lymphoma has come back or stopped responding to treatment. The main goals are to check the drug's safety, find the best dose, and see if it helps shrink tumors. Participants will receive YK…

This study tests a new drug, YK012, in people with B-cell acute lymphoblastic leukemia (B-ALL), a type of blood cancer. The goal is to check if the drug is safe and to see how well it works against the cancer. About 46 participants will take part in this early-phase trial.

This study tests a new medicine, YK012, in 189 adults with moderate to severe lupus. The goal is to see if it is safe and can help control the disease. Participants will receive the drug and be monitored for side effects and how well their lupus responds. The trial is currently r…